DM valuation problem is the uncertainty of COVID testing and the lack of AI numbers. When the AI needle will move we will be easily at 25x times the AI revenus like the AI industry. I believe in a strong 25x because of the huge positive cash-flow supported by the COVID. So to my point COVID add no or little value but is the insurance for stability. If the AI revenus can seriously be anticipated at 17M$/y for 2-3 years ahead we will hit the 1$ with solid foundations and position for upgrading the listing. If COVID testing starts to be seen as a recurring long run revenue source (still not the case) then we may think it will contribute at 10X revenues as this is not IT. In the meantime we can be anywhere depending on how people see COVID testing.
So gogogo for a well synchronized cascade of AI announcement we are lower and better positioned than any organization. DYODD